Blood Cancers

In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells.

Circulating tumor DNA predicts recurrence and splits disease into two subgroups in Stanford Medicine-led study of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.

Rosenberg combined radiation and chemotherapy to treat Hodgkin lymphoma, revolutionizing cancer care. He taught at Stanford Medicine for more than 50 years.

Hematologist Jason Gotlib wanted more effective treatments for patients with systemic mastocytosis. His research has led to the approval of two new treatments by the Food and Drug Administration.

Stanford researcher Maria Grazia Roncarolo has been awarded $12 million by the California Institute for Regenerative Medicine for a trial aimed at improving the outcomes of stem cell transplants in children and young adults with blood cancers.

EcoTyper is an algorithm that can sort out cell “ecotypes” — distinct multicellular communities — that exist in many different kinds of cancer.

CAR-T cell therapy works for many types of blood cancers, but more than half of patients relapse. A Stanford study provides a clue as to why.